PL352575A1 - Compositions of a-beta peptide and processes for producing same - Google Patents
Compositions of a-beta peptide and processes for producing sameInfo
- Publication number
- PL352575A1 PL352575A1 PL00352575A PL35257500A PL352575A1 PL 352575 A1 PL352575 A1 PL 352575A1 PL 00352575 A PL00352575 A PL 00352575A PL 35257500 A PL35257500 A PL 35257500A PL 352575 A1 PL352575 A1 PL 352575A1
- Authority
- PL
- Poland
- Prior art keywords
- compositions
- processes
- producing same
- beta peptide
- peptide
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Marine Sciences & Fisheries (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13704799P | 1999-06-01 | 1999-06-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL352575A1 true PL352575A1 (en) | 2003-08-25 |
Family
ID=22475602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL00352575A PL352575A1 (en) | 1999-06-01 | 2000-06-01 | Compositions of a-beta peptide and processes for producing same |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1181040A1 (is) |
| JP (1) | JP2003519620A (is) |
| KR (1) | KR20020016813A (is) |
| CN (1) | CN1353615A (is) |
| AR (1) | AR024558A1 (is) |
| AU (1) | AU5726100A (is) |
| BG (1) | BG106249A (is) |
| BR (1) | BR0011251A (is) |
| CA (1) | CA2374897A1 (is) |
| CZ (1) | CZ20014150A3 (is) |
| EE (1) | EE200100649A (is) |
| HK (1) | HK1045938A1 (is) |
| HR (1) | HRP20010901A2 (is) |
| IL (1) | IL146575A0 (is) |
| IS (1) | IS6182A (is) |
| MX (1) | MXPA01012355A (is) |
| NO (1) | NO20015859L (is) |
| NZ (1) | NZ515744A (is) |
| PE (1) | PE20010212A1 (is) |
| PL (1) | PL352575A1 (is) |
| RU (1) | RU2001135800A (is) |
| SK (1) | SK17012001A3 (is) |
| TR (1) | TR200103476T2 (is) |
| WO (1) | WO2000072870A1 (is) |
| ZA (1) | ZA200109704B (is) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| US7588766B1 (en) | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
| US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
| US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
| US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
| UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| AU2001268005A1 (en) | 2000-07-07 | 2002-01-21 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| AU1225702A (en) * | 2000-09-19 | 2002-04-02 | Evotec Neurosciences Gmbh | Methods and compounds for treating brain amyloidosis |
| US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
| PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| MY144532A (en) | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| TWI306458B (en) | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| EP1838348B1 (en) | 2004-12-15 | 2013-06-26 | Janssen Alzheimer Immunotherapy | Humanized amyloid beta antibodies for use in improving cognition |
| ES2396555T3 (es) | 2004-12-15 | 2013-02-22 | Janssen Alzheimer Immunotherapy | Anticuerpos que reconocen péptido beta amiloide |
| RU2442793C2 (ru) | 2005-11-30 | 2012-02-20 | Эбботт Лэборетриз | АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ |
| PL1976877T5 (pl) | 2005-11-30 | 2017-09-29 | Abbvie Inc | Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania |
| MY169492A (en) | 2006-03-23 | 2019-04-15 | Bioarctic Neuroscience Ab | Improved protofibril selective antibodies and the use thereof |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
| US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
| ES2498040T3 (es) | 2007-07-27 | 2014-09-24 | Janssen Alzheimer Immunotherapy | Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| WO2011130377A2 (en) | 2010-04-15 | 2011-10-20 | Abbott Laboratories | Amyloid-beta binding proteins |
| US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| GB201113570D0 (en) | 2011-08-05 | 2011-09-21 | Glaxosmithkline Biolog Sa | Vaccine |
| CN106661103B (zh) | 2014-07-10 | 2020-11-03 | 生命北极神经科学公司 | 改进的Aβ初原纤维结合抗体 |
| CA3008015A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release c-type natriuretic peptide agonists with increased neutral endopeptidase stability |
| EP4710947A3 (en) | 2016-01-08 | 2026-06-17 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with reduced side-effects |
| AU2017205693B2 (en) | 2016-01-08 | 2022-03-31 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with low initial NPR-B activity |
| JP6968802B2 (ja) | 2016-01-08 | 2021-11-17 | アセンディス ファーマ グロース ディスオーダーズ エー/エス | 環部分にキャリア結合を有するcnpプロドラッグ |
| RU2768747C2 (ru) | 2016-09-29 | 2022-03-24 | Асцендис Фарма Гроус Дизордерс А/С | Комбинаторная терапия с агонистами cnp контролируемого высвобождения |
| EP3923906A1 (en) | 2019-02-11 | 2021-12-22 | Ascendis Pharma Growth Disorders A/S | Dry pharmaceutical formulations of cnp conjugates |
| CN114957438B (zh) * | 2022-06-28 | 2024-04-02 | 福建亿彤生物科技有限公司 | 用于检测阿尔茨海默病的人Aβ1-42抗原决定簇多肽及制法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2980677B2 (ja) * | 1990-04-27 | 1999-11-22 | マクマイケル,ジョン | 不正常なアミロイドβタンパク質と関連する中枢神経系疾患状態の治療のための方法および組成物 |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
-
2000
- 2000-05-31 PE PE2000000521A patent/PE20010212A1/es not_active Application Discontinuation
- 2000-05-31 AR ARP000102690A patent/AR024558A1/es unknown
- 2000-06-01 BR BR0011251-8A patent/BR0011251A/pt not_active Application Discontinuation
- 2000-06-01 EE EEP200100649A patent/EE200100649A/xx unknown
- 2000-06-01 TR TR2001/03476T patent/TR200103476T2/xx unknown
- 2000-06-01 AU AU57261/00A patent/AU5726100A/en not_active Abandoned
- 2000-06-01 NZ NZ515744A patent/NZ515744A/en unknown
- 2000-06-01 KR KR1020017015474A patent/KR20020016813A/ko not_active Withdrawn
- 2000-06-01 CZ CZ20014150A patent/CZ20014150A3/cs unknown
- 2000-06-01 CA CA002374897A patent/CA2374897A1/en not_active Abandoned
- 2000-06-01 HK HK02106241.2A patent/HK1045938A1/zh unknown
- 2000-06-01 EP EP00942668A patent/EP1181040A1/en not_active Withdrawn
- 2000-06-01 SK SK1701-2001A patent/SK17012001A3/sk unknown
- 2000-06-01 MX MXPA01012355A patent/MXPA01012355A/es unknown
- 2000-06-01 PL PL00352575A patent/PL352575A1/xx not_active Application Discontinuation
- 2000-06-01 JP JP2001511317A patent/JP2003519620A/ja not_active Withdrawn
- 2000-06-01 RU RU2001135800/14A patent/RU2001135800A/ru unknown
- 2000-06-01 CN CN00808374A patent/CN1353615A/zh active Pending
- 2000-06-01 IL IL14657500A patent/IL146575A0/xx unknown
- 2000-06-01 HR HR20010901A patent/HRP20010901A2/hr not_active Application Discontinuation
- 2000-06-01 WO PCT/US2000/015302 patent/WO2000072870A1/en not_active Ceased
-
2001
- 2001-11-26 ZA ZA200109704A patent/ZA200109704B/en unknown
- 2001-11-29 IS IS6182A patent/IS6182A/is unknown
- 2001-11-30 NO NO20015859A patent/NO20015859L/no not_active Application Discontinuation
- 2001-12-20 BG BG106249A patent/BG106249A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20015859D0 (no) | 2001-11-30 |
| HRP20010901A2 (en) | 2003-04-30 |
| CZ20014150A3 (cs) | 2002-05-15 |
| JP2003519620A (ja) | 2003-06-24 |
| HK1045938A1 (zh) | 2002-12-20 |
| PE20010212A1 (es) | 2001-02-22 |
| NO20015859L (no) | 2002-02-01 |
| NZ515744A (en) | 2004-04-30 |
| IL146575A0 (en) | 2002-07-25 |
| ZA200109704B (en) | 2003-02-26 |
| AR024558A1 (es) | 2002-10-16 |
| CA2374897A1 (en) | 2000-12-07 |
| RU2001135800A (ru) | 2003-08-20 |
| CN1353615A (zh) | 2002-06-12 |
| WO2000072870A1 (en) | 2000-12-07 |
| BR0011251A (pt) | 2002-03-05 |
| MXPA01012355A (es) | 2003-06-24 |
| EE200100649A (et) | 2003-02-17 |
| EP1181040A1 (en) | 2002-02-27 |
| AU5726100A (en) | 2000-12-18 |
| SK17012001A3 (sk) | 2002-06-04 |
| IS6182A (is) | 2001-11-29 |
| TR200103476T2 (tr) | 2002-04-22 |
| BG106249A (en) | 2002-08-30 |
| KR20020016813A (ko) | 2002-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL146575A0 (en) | Compositions of a-beta peptide and processes for producing same | |
| AU4133701A (en) | Methods and compositions for peptide synthesis | |
| AP2002002515A0 (en) | Composition for ipregnation of fabrics and nettings | |
| AU2002239262A1 (en) | Compositions of peptide crystals | |
| HUP0101580A3 (en) | Pharmaceutical compositions capable of being gelled | |
| IL140214A0 (en) | Butterlike compositions and methods of manufacturing same | |
| GB9924351D0 (en) | Immunomodulation methods and compositions | |
| BG105437A (en) | REFLECTIVELY MODIFIED COMPOSITIONS AND METHODS FOR OBTAINING THEM | |
| EP1180006A4 (en) | COMPOSITIONS AND METHODS FOR PREPARING SUCH COMPOSITIONS FROM LEPIDIA | |
| HUP0101243A3 (en) | Novel compositions of eprosartan | |
| HUP0202729A3 (en) | Compositions for parenteral use of estramustine phosphate and amino acids | |
| SG120874A1 (en) | Process for the preparation of peptides | |
| GB0126643D0 (en) | Composition and process | |
| GB9926671D0 (en) | Sealing of relatively movable parts | |
| HUP9904332A3 (en) | Compositions and articles of manufacture | |
| PL337804A1 (en) | Solubilised compositions of sertralin | |
| ZA200004376B (en) | Process for the preparation of tetrapeptide | |
| ZA988450B (en) | Process for improving the plasticity of ceramic compositions and for reversing this effect | |
| GB2338234B (en) | Preparation of finasteride | |
| EP1033999A4 (en) | COMPOSITIONS CONTAINING LEUKEMIA INHIBITING FACTOR | |
| HUP0201410A3 (en) | Compositions of a-betha peptide and processes for producing same | |
| EP1100432A4 (en) | NEW APPLICATIONS OF ASCORBYL-PHOSPHORYL-CHOLESTEROL AND PREPARATIONS TO IMPLEMENT THEM | |
| EP1077892A4 (en) | METHOD AND COMPOSITION FOR IMPROVING THE UNIFORMITY OF APPLICATION OF A SIZE | |
| IL121719A (en) | Deicing composition and process of production thereof | |
| IL154785A0 (en) | Polymorphic form of finasteride and processes for the preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |